TargetMol

Jurubidine

Product Code:
 
TAR-T32323
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T32323-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Jurubidine is a type of cyclised aglycone from Jurubine.
CAS:
6084-44-2
Formula:
C27H45NO2
Molecular Weight:
415.662
Purity:
0.98
SMILES:
[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@@]5([H])C[C@@H](N)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@H](C)CO1)O2

References

1. Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff Ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Fo? R, Locatelli F, Kaspers GJL. Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL. Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528. [Epub ahead of print] PubMed PMID: 29789356. 2. Correction: Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy (doi: 10.1242/dmm.032557). Dis Model Mech. 2018 May 18;11(5). pii: dmm035501. doi: 10.1242/dmm.035501. PubMed PMID: 29784710. 3. Karmo D, Hafeez A, Halalau A, Yadav S. Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature. Case Rep Oncol Med. 2018 Mar 26;2018:8201917. doi: 10.1155/2018/8201917. eCollection 2018. PubMed PMID: 29780652; PubMed Central PMCID: PMC5892271. 4. van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, de Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018 May 17. pii: haematol.2017.187153. doi: 10.3324/haematol.2017.187153. [Epub ahead of print] PubMed PMID: 29773602.